Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 20/20 | 0.61 |
| ▸ | GUCY1A2 | P33402 | 20/20 | 0.61 |
| ▸ | GUCY1A1 | Q02108 | 20/20 | 0.61 |
| ▸ | GUCY1B1 | Q02153 | 20/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18866762 | 0.84 | GUCY1B2 (0.57) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL17611692 | 0.82 | GUCY1B2 (0.74) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082645 | 0.81 | GUCY1B2 (0.70) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082285 | 0.81 | GUCY1B2 (0.75) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16081902 | 0.80 | GUCY1B2 (0.71) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL15087454 | 0.79 | GUCY1B2 (0.63) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL17481626 | 0.79 | GUCY1B2 (0.80) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL18866735 | 0.79 | GUCY1B2 (0.47) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL23032380 | 0.79 | GUCY1B2 (0.81) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082339 | 0.79 | GUCY1B2 (0.77) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137439-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137439-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | GUCY1B2 10/4885GUCY1A2 5/4885GUCY1A1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.